Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0000950170-25-071709
Filing Date
2025-05-15
Accepted
2025-05-14 18:22:46
Documents
13
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q/A lxeo-20250331.htm   iXBRL 10-Q/A 85774
2 EX-31.1 lxeo-ex31_1.htm EX-31.1 16782
3 EX-31.2 lxeo-ex31_2.htm EX-31.2 16363
  Complete submission text file 0000950170-25-071709.txt   2226371

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lxeo-20250331.xsd EX-101.SCH 1415786
15 EXTRACTED XBRL INSTANCE DOCUMENT lxeo-20250331_htm.xml XML 7773
Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Filer) CIK: 0001907108 (see all company filings)

EIN.: 854012572 | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 001-41855 | Film No.: 25947592
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)